MC
HRTX icon

Moors & Cabot’s Heron Therapeutics HRTX Stock Holding History

Moors & Cabot’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11,250
Closed -$23.3K – 931
2025
Q2 		$23.3K Hold
11,250
– – ﹤0.01% 872
2025
Q1 		$24.8K Buy
11,250
+500
+5% +$970 ﹤0.01% 860
2024
Q4 		$16.4K Hold
10,750
– – ﹤0.01% 879
2024
Q3 		$21.4K Buy
+10,750
New +$25.7K ﹤0.01% 871

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Moors & Cabot's HRTX Position: Q3 2025 in Review

Moors & Cabot sold out of Heron Therapeutics (HRTX) in Q3 2025, closing a stake of 11,250 shares — an estimated $23.3K sold.

Moors & Cabot first reported a position in HRTX in Q3 2024 and held it in 4 quarters. The position peaked at $24.8K in Q1 2025. 172 funds tracked by Wall St. Rank hold HRTX as of Q3 2025.

  • Moors & Cabot reported no remaining Heron Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Moors & Cabot sold 11,250 Heron Therapeutics shares in Q3 2025, an estimated $23.3K.
  • Moors & Cabot first reported a position in Heron Therapeutics in Q3 2024 and held it in 4 quarters.
  • Moors & Cabot's Heron Therapeutics position peaked at $24.8K in Q1 2025.
  • 172 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2025.

Based on Moors & Cabot's 13F filing for Q3 2025, filed 14 Nov 2025.